NASDAQ:XENE

Xenon Pharmaceuticals Competitors

$17.94
-0.61 (-3.29 %)
(As of 04/21/2021 02:24 PM ET)
Add
Compare
Today's Range
$17.94
Now: $17.94
$18.40
50-Day Range
$16.66
MA: $18.93
$21.31
52-Week Range
$9.32
Now: $17.94
$21.94
Volume499 shs
Average Volume183,614 shs
Market Capitalization$642.41 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

Xenon Pharmaceuticals (NASDAQ:XENE) Vs. DCPH, CORT, ORGO, RCKT, FOLD, and GBT

Should you be buying XENE stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Xenon Pharmaceuticals, including Deciphera Pharmaceuticals (DCPH), Corcept Therapeutics (CORT), Organogenesis (ORGO), Rocket Pharmaceuticals (RCKT), Amicus Therapeutics (FOLD), and Global Blood Therapeutics (GBT).

Deciphera Pharmaceuticals (NASDAQ:DCPH) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Risk & Volatility

Deciphera Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Deciphera Pharmaceuticals and Xenon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Deciphera Pharmaceuticals03702.70
Xenon Pharmaceuticals00503.00

Deciphera Pharmaceuticals presently has a consensus price target of $70.30, suggesting a potential upside of 54.74%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 40.75%. Given Deciphera Pharmaceuticals' higher possible upside, equities research analysts plainly believe Deciphera Pharmaceuticals is more favorable than Xenon Pharmaceuticals.

Insider and Institutional Ownership

73.6% of Deciphera Pharmaceuticals shares are owned by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 7.0% of Deciphera Pharmaceuticals shares are owned by insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Deciphera Pharmaceuticals and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Deciphera PharmaceuticalsN/A-45.02%-40.12%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Valuation and Earnings

This table compares Deciphera Pharmaceuticals and Xenon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deciphera Pharmaceuticals$25 million104.72$-192,260,000.00($4.48)-10.14
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Xenon Pharmaceuticals has lower revenue, but higher earnings than Deciphera Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Insider and Institutional Ownership

75.4% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 16.4% of Corcept Therapeutics shares are owned by insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Corcept Therapeutics and Xenon Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million8.81$94.18 million$0.7729.90
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Corcept Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Corcept Therapeutics has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Profitability

This table compares Corcept Therapeutics and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics30.73%25.38%23.16%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Corcept Therapeutics and Xenon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01102.50
Xenon Pharmaceuticals00503.00

Corcept Therapeutics presently has a consensus price target of $24.00, suggesting a potential upside of 4.44%. Xenon Pharmaceuticals has a consensus price target of $25.25, suggesting a potential upside of 40.75%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Corcept Therapeutics.

Summary

Corcept Therapeutics beats Xenon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Organogenesis (NASDAQ:ORGO) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

4.6% of Organogenesis shares are owned by institutional investors. Comparatively, 79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 57.2% of Organogenesis shares are owned by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Organogenesis and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$260.98 million10.40$-40,450,000.00($0.42)-50.50
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Organogenesis has higher revenue and earnings than Xenon Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Organogenesis has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Organogenesis and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Organogenesis-1.61%-10.03%-2.22%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Recommendations

This is a summary of recent recommendations for Organogenesis and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Organogenesis00403.00
Xenon Pharmaceuticals00503.00

Organogenesis currently has a consensus price target of $16.50, indicating a potential downside of 22.21%. Xenon Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 40.75%. Given Xenon Pharmaceuticals' higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Organogenesis.

Summary

Organogenesis beats Xenon Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Rocket Pharmaceuticals (NASDAQ:RCKT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 41.4% of Rocket Pharmaceuticals shares are owned by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Rocket Pharmaceuticals and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rocket PharmaceuticalsN/AN/A$-77,270,000.00($1.58)-27.18
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Xenon Pharmaceuticals has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Rocket Pharmaceuticals has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Rocket Pharmaceuticals and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rocket PharmaceuticalsN/A-35.81%-27.52%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Recommendations

This is a summary of recent recommendations for Rocket Pharmaceuticals and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rocket Pharmaceuticals011302.93
Xenon Pharmaceuticals00503.00

Rocket Pharmaceuticals currently has a consensus price target of $59.1818, indicating a potential upside of 38.73%. Xenon Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 40.75%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Xenon Pharmaceuticals is more favorable than Rocket Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats Rocket Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Amicus Therapeutics (NASDAQ:FOLD) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.5% of Amicus Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Amicus Therapeutics and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amicus Therapeutics$182.24 million14.34$-356,390,000.00($1.31)-7.55
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Xenon Pharmaceuticals has lower revenue, but higher earnings than Amicus Therapeutics. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Amicus Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Amicus Therapeutics and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amicus Therapeutics-120.18%-73.81%-36.10%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Recommendations

This is a summary of recent recommendations for Amicus Therapeutics and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amicus Therapeutics07602.46
Xenon Pharmaceuticals00503.00

Amicus Therapeutics currently has a consensus price target of $20.0385, indicating a potential upside of 102.82%. Xenon Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 40.75%. Given Amicus Therapeutics' higher possible upside, research analysts plainly believe Amicus Therapeutics is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats Amicus Therapeutics on 8 of the 14 factors compared between the two stocks.

Global Blood Therapeutics (NASDAQ:GBT) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Institutional and Insider Ownership

79.9% of Xenon Pharmaceuticals shares are owned by institutional investors. 4.3% of Global Blood Therapeutics shares are owned by company insiders. Comparatively, 8.4% of Xenon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Global Blood Therapeutics and Xenon Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Global Blood Therapeutics$2.11 million1,239.61$-266,770,000.00($4.71)-8.93
Xenon Pharmaceuticals$6.83 million94.06$-41,600,000.00($1.54)-11.65

Xenon Pharmaceuticals has higher revenue and earnings than Global Blood Therapeutics. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Global Blood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Global Blood Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Global Blood Therapeutics and Xenon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Global Blood Therapeutics-332.94%-56.43%-39.32%
Xenon Pharmaceuticals-102.25%-21.76%-16.08%

Analyst Recommendations

This is a summary of recent recommendations for Global Blood Therapeutics and Xenon Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Global Blood Therapeutics051402.74
Xenon Pharmaceuticals00503.00

Global Blood Therapeutics currently has a consensus price target of $90.3158, indicating a potential upside of 115.45%. Xenon Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 40.75%. Given Global Blood Therapeutics' higher possible upside, research analysts plainly believe Global Blood Therapeutics is more favorable than Xenon Pharmaceuticals.

Summary

Xenon Pharmaceuticals beats Global Blood Therapeutics on 9 of the 14 factors compared between the two stocks.


Xenon Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$45.43-1.0%$2.65 billion$25 million-9.09Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.02-2.1%$2.64 billion$306.49 million25.87
Organogenesis logo
ORGO
Organogenesis
1.0$21.21-3.3%$2.62 billion$260.98 million-353.50News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$42.94-1.5%$2.61 billionN/A-23.59
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.89-1.1%$2.59 billion$182.24 million-8.60Analyst Upgrade
Insider Selling
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$42.08-1.9%$2.57 billion$2.11 million-9.11Analyst Report
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$29.62-3.2%$2.47 billion$60,000.00-9.20Analyst Revision
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.54-2.5%$2.44 billion$120.28 million-152.06Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.2$42.07-1.3%$2.41 billion$156.70 million-30.05
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$29.49-3.3%$2.32 billion$23.90 million-18.32Analyst Report
Insider Selling
Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$33.69-5.2%$2.26 billion$15 million-17.64
Cryoport logo
CYRX
Cryoport
1.7$51.74-4.1%$2.26 billion$33.94 million-89.21
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.74-1.3%$2.25 billion$963.01 million14.20
ALX Oncology logo
ALXO
ALX Oncology
1.9$55.92-2.6%$2.18 billionN/A0.00
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$53.01-3.5%$2.10 billionN/A0.00Analyst Report
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.60-2.5%$2.02 billionN/A-11.71News Coverage
MacroGenics logo
MGNX
MacroGenics
1.2$33.87-0.6%$2.02 billion$64.19 million-10.82Analyst Report
Insider Selling
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$26.79-3.7%$1.98 billion$103.54 million-20.14
Amarin logo
AMRN
Amarin
1.6$5.03-1.6%$1.95 billion$429.76 million-100.58
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.49-2.5%$1.91 billion$410,000.00-5.98
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.71-5.7%$1.89 billionN/A-19.97Unusual Options Activity
News Coverage
FibroGen logo
FGEN
FibroGen
1.8$20.43-0.4%$1.87 billion$256.58 million-7.83
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$58.22-0.4%$1.86 billionN/A-24.77
Kura Oncology logo
KURA
Kura Oncology
1.6$27.84-0.4%$1.85 billionN/A-17.08News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$25.37-0.3%$1.81 billion$26.87 million-13.28Analyst Report
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.05-2.2%$1.79 billion$34.51 million-17.14
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18
MORF
Morphic
1.3$57.56-5.7%$1.76 billion$16.98 million-36.90Insider Selling
Gap Up
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.80-1.3%$1.72 billion$428.41 million15.65Analyst Upgrade
Unusual Options Activity
News Coverage
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.77-1.7%$1.70 billion$1.63 billion14.07
Generation Bio logo
GBIO
Generation Bio
1.8$30.81-2.3%$1.70 billionN/A0.00Gap Up
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$18.10-1.8%$1.63 billion$145.97 million-7.33
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.49-2.5%$1.62 billion$392.76 million13.07Analyst Upgrade
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.95-5.8%$1.62 billionN/A-6.74Analyst Downgrade
Increase in Short Interest
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.66-2.9%$1.58 billion$2.34 million-10.03
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.82-1.4%$1.56 billionN/A0.00
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.5$35.99-7.7%$1.55 billionN/A0.00Analyst Upgrade
News Coverage
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.87-2.5%$1.52 billion$175.34 million-15.22Insider Selling
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.34-3.8%$1.51 billion$320,000.00-8.39
uniQure logo
QURE
uniQure
1.7$32.19-1.0%$1.46 billion$7.28 million-8.54Unusual Options Activity
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.49-2.3%$1.46 billion$82.27 million-18.27
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$29.65-3.3%$1.44 billionN/A-3.21Analyst Upgrade
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$62.28-1.7%$1.43 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$22.25-0.8%$1.42 billion$73.41 million-4.70News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$40.85-2.7%$1.40 billionN/A0.00
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.21-5.9%$1.40 billionN/A0.00Gap Down
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$31.89-0.5%$1.38 billion$6.20 million-13.99
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.25-2.7%$1.37 billion$19.89 million-13.33
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$27.41-3.5%$1.37 billion$4.23 million-20.30Analyst Report
Increase in Short Interest
News Coverage
Gap Down
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.